Founded in 2016 and located at Chesterford Research Park near Cambridge, UK, Microbiotica focuses on developing microbiome-based therapeutics using its proprietary microbiome profiling platform. This platform allows for the precise identification of bacterial strains associated with positive clinical outcomes in specific patient groups, driving the development of targeted LBPs.

The company’s progress is supported by key partnerships, including collaborations with Cancer Research UK, Cambridge University Hospitals, and the University of Adelaide. Additionally, the MELODY-1 study benefits from a supply agreement with Merck & Co., Inc., which provides Keytruda for the trial, emphasizing Microbiotica’s commitment to improving the effectiveness of existing cancer therapies through microbiome science.

Microbiotica has also secured additional funding to ensure the progression of these clinical trials through to their data readouts. This financial backing, which includes a Series B round in 2022, has enabled the company to continue its research and development efforts. To date, Microbiotica has raised £62 million in equity investment, with support from investors like British Patient Capital, Cambridge Innovation Capital, and Tencent. The company also receives funding from the US-based Crohn’s and Colitis Foundation, reflecting a strong interest in Microbiotica’s innovative approach to microbiome-based therapies.